AU2018351520A1 - RET9 and VEGFR2 inhibitors - Google Patents

RET9 and VEGFR2 inhibitors Download PDF

Info

Publication number
AU2018351520A1
AU2018351520A1 AU2018351520A AU2018351520A AU2018351520A1 AU 2018351520 A1 AU2018351520 A1 AU 2018351520A1 AU 2018351520 A AU2018351520 A AU 2018351520A AU 2018351520 A AU2018351520 A AU 2018351520A AU 2018351520 A1 AU2018351520 A1 AU 2018351520A1
Authority
AU
Australia
Prior art keywords
compound
disease
subject
pharmaceutically acceptable
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018351520A
Other languages
English (en)
Inventor
Pawel Wojciech Nowak
Winston Zapanta ONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of AU2018351520A1 publication Critical patent/AU2018351520A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
AU2018351520A 2017-10-20 2018-10-19 RET9 and VEGFR2 inhibitors Abandoned AU2018351520A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575280P 2017-10-20 2017-10-20
US62/575,280 2017-10-20
PCT/US2018/056751 WO2019079747A1 (fr) 2017-10-20 2018-10-19 Inhibiteurs de ret9 et vegfr2

Publications (1)

Publication Number Publication Date
AU2018351520A1 true AU2018351520A1 (en) 2020-05-07

Family

ID=64277798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018351520A Abandoned AU2018351520A1 (en) 2017-10-20 2018-10-19 RET9 and VEGFR2 inhibitors

Country Status (10)

Country Link
US (1) US11401260B2 (fr)
EP (1) EP3697775A1 (fr)
JP (1) JP2021500346A (fr)
KR (1) KR20200074179A (fr)
CN (1) CN111465601A (fr)
AU (1) AU2018351520A1 (fr)
BR (1) BR112020007787A2 (fr)
CA (1) CA3079673A1 (fr)
MX (1) MX2020007183A (fr)
WO (1) WO2019079747A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080015482A (ko) * 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
CA2473572C (fr) * 2002-02-01 2011-05-10 Astrazeneca Ab Composes de quinazoline
AU2014219024B2 (en) * 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
AU2014342042B2 (en) * 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
CA3079673A1 (fr) 2019-04-25
CN111465601A (zh) 2020-07-28
US11401260B2 (en) 2022-08-02
EP3697775A1 (fr) 2020-08-26
MX2020007183A (es) 2021-03-31
BR112020007787A2 (pt) 2020-10-06
WO2019079747A1 (fr) 2019-04-25
KR20200074179A (ko) 2020-06-24
US20210179582A1 (en) 2021-06-17
JP2021500346A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
US11713323B2 (en) Crystalline forms of therapeutic compounds and uses thereof
AU2014219024B2 (en) Therapeutic compounds and uses thereof
AU2014216178B2 (en) Therapeutic compounds and uses thereof
JP2016510044A (ja) 癌などの疾患の処置のためのトリアゾロ［４，５−ｄ］ピリミジン誘導体
JP7058885B2 (ja) 尿素誘導体及びその使用
US9688688B2 (en) Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014341966B2 (en) Crystalline forms of therapeutic compounds and uses thereof
AU2014275198B2 (en) Novel compounds and uses thereof
US11401260B2 (en) Biochemical binding of RET9 and VEGFR2 inhibitors
US20170260193A1 (en) Crystalline Forms of Therapeutic Compounds and Uses Thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period